Intimal redox stress: Accelerated atherosclerosis in metabolic syndrome and type 2 diabetes mellitus. Atheroscleropathy

Cardiovascular Diabetology

Volumn 1, Issue , 2002, Pages

  Hayden, Melvin R ^a   Tyagi, Suresh C ^b  

^a University of Missouri   (United States)

^b UNIVERSITY OF MISSISSIPPI MEDICAL CENTER   (United States)

Author keywords

Atheroscleropathy; Atherosclerosis; Oxidative stress; Reductive stress; RNS (reactive nitrogen species); ROS (reactive oxygen species)

Indexed keywords

REACTIVE OXYGEN METABOLITE;

ARTERY INTIMA; ARTERY WALL; ATHEROGENESIS; ATHEROSCLEROSIS; HUMAN; IMPAIRED GLUCOSE TOLERANCE; INSULIN RESISTANCE; METABOLIC SYNDROME X; MORBIDITY; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OXIDATION REDUCTION STATE; OXIDATIVE STRESS; PATHOPHYSIOLOGY; REVIEW; RISK REDUCTION;

EID: 0042660281     PISSN: 14752840     EISSN: None     Source Type: Journal    
DOI: 10.1186/1475-2840-1-3     Document Type: Review

References (143)

1. Hayden MR, Tyagi SC: Arterial vascular remodeling: the endothelial cell's central role. Mo Med 1998, 95(5):213-217
2. Hayden MR, Tyagi SC: Chapter. Atherosclerosis: Implications of angiotensin II and the AT-1 receptor. Angiotensin II Receptor Blockade: Physiological and Clinical Implications (Edited by: Dhalla NS, Zahradka P, Dixon I, Beamish R) Kluwer Academic publishers. Boston, Ma 1998, 2:233-243
3. Hayden MR, Tyagi SC: Arteriogenesis: Angiogenesis within Unstable Atherosclerotic Plaques - Interactions with Extracellular Matrix. Curr Interv Cardiol Rep 2000, 3:218-227
4. Hayden MR: Atherosclerosis and Plaque Angiogenesis: A Malignant Transformation. Submitted paper. Pathology and Clinical classification of Vulnerable Plaque. VP.org 2001, 3:[http://www.vp.org] [http://www.vp.org/ResourceCenter/ Pete_Hayden_Angiogenesis.html]
5. Joslin EP: Arteriosclerosis and Diabetes. Annals of Clinical Medicine 1927, 5(13):1061-1079
6. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 2001, 285:2486-2497
7. Oberley LW: Free radical and diabetes. Free Radic Bio Med 1988, 5:113-124
8. Hayden MR, Tyagi SC: "A" is for amylin and amyloid in type 2 diabetes mellitus. JOP. J Pancreas (Online) 2001, 2(4):124-139 [www.joplink.net]
9. Hayden MR, Tyagi SC: Islet redox stress: the manifold toxicities of insulin resistance, metabolic syndrome, and amylin derived islet amyloid in type 2 diabetes mellitus. JOP. J Pancreas (Online) 2002, 3(4):86-108 [www.joplink.net]
10. Kylin E: Studien ueber das Hypertonie-Hyperglyka"mie-Hyperurika" miesyndrom. Zentralblatt fuer Innere Medizin 1923, 44:105-127
11. Himsworth H: Diabetes mellitus: a differentiation into insulin-sensitive and insulin-insensitive types. Lancet 1936, 1:127-130
12. Yalow RS, Glick SM, Roth J, Berson SA: Plasma insulin and growth hormone levels in obesity and diabetes. Ann NY Acad Sci 1965, 131(1):357-373
13. Reaven GM: Banting Lecture 1988. Role of insulin resistance in human disease. Diabetes 1988, 37:1595-1607
14. Alberti KGM, Zimmet PZ, For the WHO Consultation: Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: Diagnosis and classification of diabetes mellitus, provisional report of a WHO consultation. Diabet Med 1998, 15:539-553
15. Ford ES, Giles WH, Dietz WH: Prevalence of the metabolic syndrome among US adults:Findings from the third national health and nutrition examination survey. JAMA 2002, 287(3):356-359
16. Jones LC, Clark A: Beta cell neogenesis in type 2 diabetes mellitus. Diabetes 2001, 50(Suppl 1):S186-S187
17. Guiot Y, Sempoux C, Moulin P, Rahier J: No decrease of the beta cell mass in type 2 patients. Diabetes 2001, 50(Suppl 1):S188
18. Reaven GM: Banting Lecture 1988. Role of insulin resistance in human disease. Diabetes 1988, 37:1595-1607
19. Reaven GM: Metabolic syndrome: pathophysiology and implications for management of cardiovascular disease. Circulation 2002, 106(3):286-288
20. Tahmasebi M, Puddefoot JR, Inwang ER, Vinson GP: The tissue renin-angiotensin system in human pancreas. J Endocrinol 1999, 161:317-322
21. Carlsson PO: The renin-angiotensin system in the endocrine pancreas. JOP. J Pancreas (Online) 2001, 2:26-32
22. Nickenig G, Roling J, Strehlow K, Schnabel P, Bohm M: Insulin induces upregulation of vascular AT-1 receptor gene expression by posttranscriptional mechanisms. Circulation 1998, 98:2453-2460
23. Folli F, Saad MJ, Velloso L, Hansen H, Carandente O, Feener EP, Kahn CR: Crosstalk between insulin and angiotensin II signalling systems. Exp Clin Endocrinol Diabetes 1999, 107:133-139
24. Cooper ME, McNally PG, Phillips PA, Johnston CI: Amylin stimulates plasma renin concentrations in humans. Hypertension 1995, 26:460-464
25. Ikeda T, Iwata K, Ochi H: Effect of insulin, proinsulin, and amylin on renin release from perfused rat kidney. Metabolism 2001, 50:763-766
26. Griendling KK, Sorescu D, Ushio-Fukai M: NAD(P)H oxidase: role in cardiovascular biology and disease. Circ Res 2000, 86:494-501
27. Munzel T, Keaney JF Jr: Are ACE inhibitors a "magic bullet" against oxidative stress? Circulation 2001, 104:1571-1574
28. Heart Outcomes Prevention Evaluation (HOPE) Study Investigators: Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 2000, 355:253-259
29. Griendling KK, Harrison DG: Out, damned dot: studies of the NADPH oxidase in atherosclerosis. J Clin Invest 2001, 108:1423-1424
30. Williamson JR, Kilo C: Glucotoxicity and diabetic vascular disease. Medical Dialogue on Diabetes 1989, 8:8-10
31. Fujimori E: Cross-linking and fluorescence changes of collagen by glycation and oxidation. Biochim Biophys Acta 1989, 998:105-110
32. Dills WL Jr: Protein fructosylation: fructose and the Maillard reaction. Am J Clin Nutr 1993, 58(5 Suppl):779-787S
33. McPherson JD, Shilton BH, Walton DJ: Role of fructose in glycation and cross-linking of proteins. Biochemistry 1998, 27:1901-1907
34. Aronson D, Rayfield EJ: How hyperglycemia promotes atherosclerosis: molecular mechanisms. Cardiovasc Diabetol 2002, 1(1):1 [http://www.biomedcentral.com/1475-2840/1/1]
35. Wendt T, Bucciarelli L, Qu W, Lu Y, Yan SF, Stern DM, Schmidt AM: Receptor for advanced glycation endproducts (RAGE) and vascular inflammation: insights into the pathogenesis of macrovascular complications in diabetes. Curr Atheroscler Rep 2002, 4:228-237
36. Yan SD, Zhu H, Zhu A, Golabek A, Du H, Roher A, et al: Receptor-dependent cell stress and amyloid accumulation in systemic amyloidosis. Nat Med 2000, 6:643-651
37. Arai K, Iizuka S, Tada Y, Oikawa K, Taniguchi N: Increase in the glycosylated form of erythrocyte CuZnSOD in diabetes and close association of non-enzymatic glycosylation with enzyme activity. Biochim Biophys Acta 1987, 924:292-296
38. Chari SN, Nath N, Rathi AB: Glutathione and its redox system in diabetic polymorphonuclear leukocytes. Am J Med Sci 1984,287:14-15
39. Jennings PE, Chirico S, Jones AF, Lunec J, Barnett AH: Vitamin C metabolites and microangiopathy in diabetes mellitus. Diabetes Res 1987, 6:151-154
40. Sinclair AJ, Lunec J, Girling AJ, Barnett AH: Modulators of free radical activity in diabetes mellitus: role of ascorbic acid. EXS 1992, 62:151-154
41. Giugliano D, Ceriello A, Paolisso G: Diabetes mellitus, hypertension, and cardiovascular disease: which role for oxidative stress? Metabolism 1995, 44:363-368
42. Duplain H, Burcelin R, Sartori C, Cook S, Egli M, Lepori M, Scherrer U, et al: Insulin resistance, hyperlipidemia, and hypertension in mice lacking endothelial nitric oxide synthase. Circulation 2001, 104:342-345
43. Miyamoto Y, Saito Y, Kajiyama N, Yoshimura M, Shimasaki Y, Nakayama M, et al: Endothelial nitric oxide synthase gene is positively associated with essential hypertension. Hypertension 1998, 32:3-8
44. Stuhlinger MC, Abbasi F, Chu JW, Lamendola C, McLaughlin TL, Cooke JP, Reaven GM, Tsao PS: Relationship between insulin resistance and an endogenous nitric oxide synthase inhibitor. JAMA 2002, 287(11):1420-1426
45. Nash DT: Insulin resistance, ADMA levels, and cardiovascular disease. JAMA 2002, 287(11):1451-1452
46. Christ M, Bauersachs J, Liebetrau C, Heck M, Gunther A, Wehling M: Glucose Increases Endothelial-Dependent Superoxide Formation in Coronary Arteries by NAD(P)H Oxidase Activation: Attenuation by the 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitor Atorvastatin. Diabetes 2002, 51(8):2648-2652
47. Stepp DW, Ou J, Ackerman AW, Welak S, Klick D, Pritchard KA Jr: Native LDL and minimally oxidized LDL differentially regulate superoxide anion in vascularendothelium in situ. Am J Physiol Heart Circ Physiol 2002, 283(2):H750-759
48. Zou MH, Shi C, Cohen RA: Oxidation of the zinc-thiolate complex and uncoupling of endothelial nitric oxide synthase by peroxynitrite. J Clin Invest 2002, 109(6):817-826
49. Verma S, Wang CH, Li SH, Dumont AS, Fedak PW, Badiwala MV, Dhillon B, Weisel RD, Li RK, Mickle DA, Stewart DJ: A self fulfilling prophecy: C-reactive protein attenuates nitric oxide production and inhibits angiogenesis. Circulation 2002, 106(8):913-919
50. Guzik TJ, Mussa S, Gastaldi D, Sadowski J, Ratnatunga C, Pillai R, Channon KM: Mechanisms of increased vascular superoxide production in human diabetes mellitus: role of NAD(P)H oxidase and endothelial nitric oxide synthase. Circulation 2002, 105(14):1656-1662
51. Vasquez-Vivar J, Kalyanaraman B, Martasek P, Hogg N, Masters BS, Karoui H, Tordo P, Pritchard KA Jr: Superoxide generation by endothelial nitric oxide synthase: the influence of cofactors. Proc Natl Acad Sci U S A 1998, 95(16):9220-9225
52. Wong TY, Klein R, Sharrett AR, Schmidt MI, Pankow JS, Couper DJ, Klein BE, Hubbard LD, Duncan BB: Retinal arteriolar narrowing and risk of diabetes mellitus in middle-aged persons. JAMA 2002, 287(19):2528-2533
53. Hayden MR: Islet Amyloid, Metabolic Syndrome, and the Natural Progressive History of Type 2 Diabetes Mellitus. JOP. J Pancreas (Online) 2002, 3(5):126-138 [www.joplink.net]
54. Hoffmann J, Haendeler J, Aicher A, Rossig L, Vasa M, Zeiher AM, Dimmeler S: Aging enhances the sensitivity of endothelial cells toward apoptotic stimuli: important role of nitric oxide. Circ Res 2001, 89:709-715
55. Harman D: Extending functional life span. Exp Gerontol 1998, 33:95-112
56. Lenaz G: Role of mitochondria in oxidative stress and ageing. Biochim Biophys Acta 1998, 1366:53-67
57. Ye JM, Lim-Fraser M, Cooney GJ, Cooper Gj, Iglesias MA, Watson DG, et al: Evidence that amylin stimulates lipolysis in vivo: a possible mediator of induced insulin resistance. Am J Physiol Endocrinol Metab 2001, 280:E562-569
58. Yan SD, Schmidt AM, Anderson GM, Zhang J, Brett J, Zou YS, et al: Enhanced cellular oxidant stress by the interaction of advanced glycation end products with their receptors/binding proteins. J Biol Chem 1994, 269:9889-9897
59. Janson J, Ashley RH, Harrison D, McIntyre S, Butler PC: The mechanism of islet amyloid polypeptide toxicity is membrane disruption by intermediate-sized toxic amyloid particles. Diabetes 1999, 48:491-498
60. Williamson JR, Kilo C, Ido Y: The role of cytosolic reductive stress in oxidant formation and diabetic complications. Diabetes Res Clin Pract 1999, 45:81-82
61. Ido Y, Kilo C, Williamson JR: Interactions between the sorbitol pathway, non-enzymatic glycation, and diabetic vascular dysfunction. Nephrol Dial Transplant 1996, 11(Suppl 5):72-75
62. Williamson JR, Chang K, Frangos M, Hasan KS, Ido Y, Kawamura T, et al: Hyperglycemic Pseudohypoxia and diabetic complications. Diabetes 1993, 42:801-813
63. Abaci A, Oguzhan A, Kahraman S, Eryol NK, Unal S, Arinc H, Ergin A: Effect of diabetes mellitus on formation of coronary collateral vessels. Circulation 1999, 99(17):2239-2242
64. McGarry JD: Banting lecture 2001: dysregulation of fatty acid metabolism in the etiology of type 2 diabetes. Diabetes 2002, 51:7-18
65. Bakker SJ, IJzerman RG, Teerlink T, Westerhoff HV, Gans RO, Heine RJ: Cytosolic triglycerides and oxidative stress in central obesity: the missing link between excessive atherosclerosis, endothelial dysfunction, and beta cell failure? Atherosclerosis 2000, 148:17-21
66. Gotto AM Jr: Triglyceride as a risk factor for coronary artery disease. Am J Cardiol 1998, 82:22-25Q
67. Grundy SM: Hypertriglyceridemia, atherogenic dyslipidemia, and the metabolic syndrome. Am J Cardiol 1998, 81:18-25B
68. Lamarche B, Tchernof A, Mauriege P, Cantin B, Dagenais GR, Lupien PJ, Despres JP: Fasting insulin and apolipoprotein B levels and low-density lipoprotein particle size as risk factors for ischemic heart disease. JAMA 1998, 279:1955-1961
69. Williams KJ, Tabas I: The response-to-retention hypothesis of early atherogenesis. Arterioscler Thromb Vasc Biol 1995, 15:551-561
70. Williams KJ, Tabas I: The response-to-retention hypothesis of atherogenesis reinforced. Curr Opin Lipidol 1998, 9:471-474
71. Unger RH, Orci L: Diseases of liporegulation:new perspective on obesity and related disorders. FASEB J 2001, 15:312-21
72. Lee Y, Hirose H, Ohneda M, Johnson JH, McGarry JD, Unger RH: Beta-cell lipotoxicity in the pathogenesis of non-insulin-dependent diabetes mellitus of obese rats: Impairment in adipocyte beta-cell relationships. Proc Natl Acad Sci USA 1994, 91:10878-10882
73. Lee Y, Hirose H, Zhou YT, Esser V, McGarry JD, Unger RH: Increased lipogenic capacity of the islets of obese rats. A role in the pathogenesis of NIDDM. Diabetes 1997, 46:408-413
74. Shimabukuro M, Zhou YT, Levi M, Unger RH: Fatty acid-induced beta cell apoptosis: a link between obesity and diabetes. Proc Natl Acad Sci USA 1998, 95:2498-2502
75. Shimabukuro M, Higa M, Zhou YT, Wang MY, Newgard CB, Unger RH: Lipoapoptosis in beta-cells of obese prediabetic fa/fa rats. Role of serine palmitoyl transferase overexpression. J Biol Chem 1998, 273:487-490
76. Unger RH: Lipotoxicity in the pathogenesis of obesity-dependent NIDDM. Genetic and clinical implications. Diabetes 1995, 44:863-870
77. Obeid LM, Linardic CM, Karolak LA, Hannun YA: Programmed cell death induced by ceramide. Science 1993, 259:239-247
78. Katsuyama K, Shichiri M, Marumo F, Hirata Y: Role of nuclear factor kappa B activation in cytokine- and sphingomyelinase-stimulated inducible nitric oxide synthase gene expression in vascular smooth muscle cells. Endocrinology 1998, 139:4506-4512
79. Zethelius B, Byberg L, Hales CN, Lithell H, Berne C: Proinsulin is an independent predictor of coronary heart disease: Report from a 27-year follow-up study. Circulation 2002, 105(18):2153-2158
80. Yudkin JS, May M, Elwood P, Yarnell JW, Greenwood R, Davey Smith G: Concentrations of proinsulin like molecules predict coronary heart disease risk independently of insulin: prospective data from the Caerphilly Study. Diabetologia 2002, 45(3):327-336
81. Libby P: Atherosclerosis: the new view. Sci Am 2002, 286(5):46-55
82. Ross R: Atherosclerosis - an inflammatory disease. N Engl J Med 1999, 340(2):115-126
83. Pradhan AD, Manson JE, Rifai N, Buring JE, Ridker PM: C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA 2001, 286(3):327-334
84. Pradhan AD, Ridker PM: Do atherosclerosis and type 2 diabetes share a common inflammatory basis? Eur Heart J 2002, 23(11):831-834
85. Ridker PM, Hennekens CH, Buring JE, Rifai N: C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000, 342(12):836-843
86. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH: Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 1997, 336(14):973-979
87. Duncan BB, Schmidt MI: Chronic activation of the innate immune system may underlie the metabolic syndrome. Sao Paulo Med J 2001, 119(3):122-127
88. Pickup JC, Crook : Is type II diabetes mellitus a disease of the innate immune system? Diabetologia 1998, 41(10):1241-1248
89. Pickup JC, Mattock MB, Chusney GD, Burt D: NIDDM as a disease of the innate immune system: association of acute-phase reactants and interleukin-6 with metabolic syndrome X. Diabetologia 1997, 40(11):1286-1292
90. Yudkin JS, Kumari M, Humpries SE, Mohamed-Ali V: Inflammation, obesity, stress and coronary heart disease: is intrleukin-6 the link? Atherosclerosis 2000, 148:209-214
91. Wajchenberg BL: Subcutaneous and visceral adipose tissue: Their relation to the metabolic syndrome. Endocrine Reviews 2000, 21(6):697-738
92. Lemieux I, Pascot A, Prud'homme D, Almeras N, Bogaty P, Nadeau A, Bergeron J, Despres JP: Elevated C-Reactive protein. Another component of the atherothrombotic profile of abdominal obesity. Arteriosclerosis Thrombosis and Vascular Biology 2001, 21:961-967
93. Naghavi M, Madjid M, Khan MR, Mohammadi RM, Willerson JT, Casscells SW: New developments in the detection of vulnerable plaque. Curr Atheroscler Rep 2001, 3(2):125-135
94. Naghavi M, John R, Naguib S, Siadaty MS, Grasu R, Kurian KC, van Winkle WB, Soller B, Litovsky S, Madjid M, Willerson JT, Casscells W: pH Heterogeneity of human and rabbit atherosclerotic plaques; a new insight into detection of vulnerable plaque. Atherosclerosis 2002, 164(1):27-35
95. Wang J, Geng YJ, Guo B, Klima T, Lal BN, Willerson JT, Casscells W: Near-infrared spectroscopic characterization of human advanced atherosclerotic plaques. J Am Coll Cardiol 2002, 39(8):1305-1313
96. Casscells W, Hathorn B, David M, Krabach T, Vaughn WK, McAllister HA, Bearman G, Willerson JT: Thermal detection of cellular infiltrates in living atherosclerotic plaques: possible implications for plaque rupture and thrombosis. Lancet 1996, 347(9013):1447-1451
97. Duncan BB, Schmidt MI: Chronic activation of the innate immune system may underlie the metabolic syndrome. Sao Paulo Med J 2001, 199:122-127
98. Vozarova B, Weyer C, Lindsay RS, Pratley RE, Bogardus C, Tataranni PA: High white blood cell count is associated with a worsening of insulin sensitivity and predicts the development of type 2 diabetes. Diabetes 2002, 51:455-461
99. Thomas HE, Darwiche R, Corbett JA, Kay TW: Interleukin-1 plus gamma-interferon-induced pancreatic beta-cell dysfunction is mediated by beta-cell nitric oxide production. Diabetes 2002, 51:311-316
100. Duncan BB, Schmidt MI, Offenbacher S, Wu KK, Savage PJ, Heiss G: Factor VIII and other hemostasis variables are related to incident diabetes in adults. The Atherosclerosis Risk in Communities (ARIC) Study. Diabetes Care 1999, 22:767-772
101. Droge W: Free radicals in the physiological control of cell function. Physiol Rev 2002, 82:47-95
102. Chung HY, Kim HJ, Kim JW, Yu BP: The inflammation hypothesis of aging: molecular modulation by calorie restriction. Ann N Y Acad Sci 2001, 928:327-335
103. Syed MA, Barinas-Mitchell E, Pietropaolo SL, Zhang YJ, Henderson TS, Kelley DE, Korytkowski MT, Donahue RP, Tracy RP, Trucco M, Kuller LH, Pietropaol M: Is type 2 diabetes a chronic inflammatory/autoimmune disease? Diabetes Nutr Metab 2002, 15(2):68-83
104. Pietropaolo M, Barinas-Mitchell E, Pietropaolo SL, Kuller LH, Trucco M: Evidence of islet cell autoimmunity in elderly patients with type 2 diabetes. Diabetes 2000, 49(1):32-38
105. Zimmet PZ, Tuomi T, Mackay IR, Rowley MJ, Knowles W, Cohen M, Lang DA: Latent autoimmune diabetes mellitus in adults (LADA): the role of antibodies to glutamic acid decarboxylase in diagnosis and prediction of insulin dependency. Diabet Med 1994, 11(3):299-303
106. Litchfield JE, Thorpe SR, Baynes JW: Oxygen is not required for the browning and crosslinking of protein by pentoses: relevance to Maillard reactions in vivo. Int J Biochem Cell Biol 1999, 31:1297-1305
107. Fu MX, Wells-Knecht KJ, Blackledge JA, Lyons TJ, Thorpe SR, Baynes JW: Glycation, glycoxidation, and cross-linking of collagen by glucose. Kinetics, mechanisms, and inhibition of late stages of the Maillard reaction. Diabetes 1994, 43:676-683
108. Hunt JV, Smith CC, Wolff SP: Autoxidative glycosylation and possible involvement of peroxides and free radicals in LDL modification by glucose. Diabetes 1990, 39:1420-1424
109. Brodsky SV, Morrishow AM, Dharia N, Gross SS, Goligorsky MS: Glucose scavenging of nitric oxide. Am J Physiol Renal Physiol 2001, 280:F480-486
110. Ihara Y, Toyokuni S, Uchida K, Odaka H, Tanaka T, Ikeda H, et al: Hyperglycemia causes oxidative stress in pancreatic beta-cells of GK rats, a model of type 2 diabetes. Diabetes 1999, 48:927- 932
111. Poitout V, Robertson RP: Minireview. Secondary beta-cell failure in type 2 diabetes. A convergence of glucotoxicity and lipotoxicity. Endocrinology 2002, 143:339-442
112. Nishikawa T, Edelstein D, Du XL, Yamagishi S, Matsummura T, Kaneda Y, Yorek MA, Beebe D, Oates PJ, Hammes HP, Giardino I, Brownlee M: Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage. Nature 2000, 404(6779):787-790
113. Pennathur S, Wagner JD, Leeuwenburg C, Litwak KN, Heinecke JW: A hydroxyl radical-like species oxidizes cynomologus monkey artery wall proteins in early diabetic vascular disease. J Clin Invest 2001, 107(7):853-860
114. Berry C, Brosnan MJ, Fennell J, Hamilton CA, Dominiczak AF: Oxidative stress and vascular damage in hypertension. Curr Opin Nephrol Hypertens 2001, 10:247-255
115. Kailasam MT, Parmer RJ, Tyrell EA, Henry RR, O'Connor DT: Circulating amylin in human essential hypertension: heritability and early increase in individuals at genetic risk. J Hypertens 2000, 18:1611-1620
116. Sowers JR: Update on the cardiometabolic syndrome. Clin Cornerstone 2001, 4:17-23
117. McFarlane SI, Banerji M, Sowers JR: Insulin resistance and cardiovascular disease. J Clin Endocrinol Metab 2001, 86:713-718
118. Jacques PF, Bostom AG, Williams RR, Ellison RC, Eckfeldt JH, Rosenberg IH, et al: Relation between folate status, a common mutation in methylenetetrahydrofolate reductase, and plasma homocysteine concentrations. Circulation 1996, 93:7-9
119. Arruda VR, von Zuben PM, Chiaparini LC, Annichino-Bizzacchi JM, Costa FF: The mutation Ala677-Val in the methylene tetrahydrofolate reductase gene: a risk factor for arterial disease and venous thrombosis. Thromb Haemost 1997, 77:818-821
120. Feix A, Fritsche-Polanz R, Kletzmayr J, Vychytil A, Horl WH, Sunder-Plassmann G, Fodinger M: Increased prevalence of combined MTR and MTHFR genotypes among individuals with severely elevated total homocysteine plasma levels. Am J Kidney Dis 2001, 38:956-964
121. Woo KS, Chook P, Lolin YI, Sanderson JE, Metreweli C, Celermajer DS: Folic acid improves arterial endothelial function in adults with hyperhomocystinemia. J Am Coll Cardiol 1999, 34:2002-2006
122. Audelin MC, Genest J Jr: Homocysteine and cardiovascular disease in diabetes mellitus. Atherosclerosis 2001, 159:497-511
123. Fodinger M, Mannhalter C, Wolfl G, Pabinger I, Muller E, Schmid R, et al: Mutation (677 C to T) in the methylenetetrahydrofolate reductase gene aggravates hyperhomocysteinemia in hemodialysis patients. Kidney Int 1997, 52:517-523
124. Weiss N, Heydrick S, Zhang YY, Bierl C, Cap A, Loscalzo J: Cellular redox state and endothelial dysfunction in mildly hyperhomocysteinemic cystathionine beta-synthase-deficient mice. Arterioscler Thromb Vasc Biol 2002, 22:34-41
125. Simon DI, Mullins ME, Jia L, Gaston B, Singel DJ, Stamler JS: Polynitrosylated proteins: characterization, bioactivity and functional consequences. Proc Natl Acad Sci USA 1996, 93:4736-4741
126. Beckman JS, Koppenol WH: Nitric oxide, superoxide, and peroxynitrite: the good, the bad, and ugly. Am J Physiol 1996, 271:C1424-1437
127. Beckman JS, Beckman TW, Chen J, Marshall PA, Freeman BA: Apparent hydroxy radical production by peroxinitrite:Implications for endothelial injury from nitric oxide and superoxide. Proc Natl Acad Sci USA 1990, 87:1620-1624
128. Mujumdar VS, Aru GM, Tyagi SC: Induction of oxidative stress by homocyst(e)ine impairs endothelial function. J Cell Biochem 2001, 82:491-500
129. Maejima K, Nakano S, Himeno M, Tsuda S, Makiishi H, Ito T, et al: Increased basal levels of plasma nitric oxide in Type 2 diabetic subjects. Relationship to microvascular complications. J Diabetes Complications 2001, 15:135-143
130. Zhang X, Li H, Jin H, Ebin Z, Brodsky S, Goligorsky MS: Effects of homocysteine on endothelial nitric oxide production. Am J Physiol Renal Physiol 2000, 279:F671-678
131. Li H, Lewis A, Brodsky S, Rieger R, Iden C, Goligorsky MS: Homocysteine induces 3-hydroxy-3-methylglutaryl coenzyme A reductase in vascular endothelial cells. A mechanism for development of atherosclerosis? Circulation 2002, 105:1037-1043
132. Stuhlinger MC, Tsao PS, Her JH, Kimoto M, Balint RF, Cooke JP: Homocysteine impairs the nitric oxide synthase pathway: role of asymmetric dimethylarginine. Circulation 2001, 104(21):2569-2575
133. Kahn SE, Andrikopoulos S, Verchere CB: Islet amyloid:a long-recognized but underappreciated pathological feature of type 2 diabetes. Diabetes 1999, 48:241-253
134. Wang F, Hull RL, Vidal J, Cnop M, Kahn SE: Islet amyloid develops diffusely throughout the pancreas before becoming severe and replacing endocrine cells. Diabetes 2001, 50:2514-2520
135. Uemura S, Matsushita H, Li W, Glassford AJ, Asagami T, Lee KH, et al: Diabetes mellitus enhances vascular matrix metalloproteinase activity: role of oxidative stress. Circ Res 2001, 88:1291-1298
136. Janson J, Ashley RH, Harrison D, McIntyre S, Butler PC: The mechanism of islet amyloid polypeptide toxicity is membrane disruption by intermediate-sized toxic amyloid particles. Diabetes 1999, 48:491-498
137. Johnson PJ, Tyagi SC, Katwa LC, Ganjam VK, Moore LA, Kreeger JM, Messer NT: Activation of extracellular matrix metalloproteinases in equine laminitis. Vet Rec 1998, 142:392-396
138. Finkel T: Reactive oxygen species and signal transduction. IUBMB Life 2001, 52:3-6
139. Reiling J: JAMA 100 years ago: February 8, 1902. JAMA 2002, 287:692
140. Diabetes as a manifold disease. JAMA 1902, 38:402-408
141. Beckman JA, Creager MA, Libby P: Diabetes and atherosclerosis: epidemiology, pathophysiology, and management. JAMA 2002, 287(19):2570-2581
142. Dagogo-Jack S: Preventing diabetes-related morbidity and mortality in the primary care setting. J Natl Med Assoc 2002, 94(7):549-560
143. Moneva MH, Dagogo-Jack S: Multiple drug targets in the management of type 2 diabetes. Curr Drug Targets 2002, 3(3):203-221